Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $32.57 USD
Change Today +0.67 / 2.10%
Volume 2.9M
HZNP On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Connaught House

1st Floor

1 Burlington Road

Dublin, 4

Ireland

Phone: 353 1 772 2100

Fax:

Horizon Pharma plc, a specialty biopharmaceutical company, focuses on improving patients’ lives by identifying, developing, acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company’s U.S. marketed products are ACTIMMUNE (interferon gamma-1b), DUEXIS (ibuprofen/famotidine), PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%), RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The company markets its products in the United States through its field sales force. ACTIMMUNE ACTIMMUNE is a biologically manufactured protein called interferon gamma-1b that is similar to a protein the human body makes naturally. In the body, interferon gamma is produced by cells of the immune system and helps to prevent infection in patients with chronic granulomatous disease (CGD) and enhances osteoclast function in patients with severe, malignant osteopetrosis (SMO). ACTIMMUNE is approved by the U.S. Food and Drug Administration (FDA) to reduce the frequency and severity of serious infections associated with CGD and for delaying time to disease progression in patients with SMO. ACTIMMUNE is the drug approved by the FDA for the treatment for CGD and SMO and the company markets and distributes ACTIMMUNE only in the United States. The company’s licenses allow it to market and sell ACTIMMUNE in the United States, Canada, and Japan. DUEXIS DUEXIS is a proprietary single tablet formulation containing a fixed-dose combination of ibuprofen, the most widely prescribed nonsteroidal anti-inflammatory drugs (NSAID), and famotidine, a gastrointestinal (GI) agent used to treat dyspepsia, gastroesophageal reflux disease, or GERD, and active ulcers, in one pill. Ibuprofen has proven anti-inflammatory and analgesic properties and famotidine reduces the stomach acid secretion that can cause upper GI ulcers. DUEXIS is indicated for the relief of signs and symptoms of rheumatoid arthritis (RA) and osteoarthritis (OA) and to decrease the risk of developing GI ulcers in patients who are taking ibuprofen for these indications. The company has a contract with BASF Corporation, or BASF, for the purchase of DC85, which is ibuprofen in a direct compression blend and is the active ingredient in DUEXIS. Pursuant to the agreement, the company is obligated to purchase a significant majority of its commercial demand for DC85 from BASF. The contract expires in December 2017. The company has a manufacturing and supply agreement with sanofi-aventis U.S. Pursuant to the agreement, sanofi-aventis U.S. is obligated to manufacture and supply DUEXIS to the company in final, packaged form, and it is obligated to purchase DUEXIS exclusively from sanofi-aventis U.S. for its commercial requirements of DUEXIS in North America and certain countries and territories in Europe, including the European Union member states and Scandinavia, and South America. The company has a collaboration, license and supply agreement with Grünenthal S.A for the potential commercialization of DUEXIS in certain Latin American and Caribbean countries. PENNSAID 2% PENNSAID 2% is a topical NSAID that is applied directly to the knee and is indicated for the treatment of pain of OA of the knee(s). PENNSAID 2% contains diclofenac sodium, a commonly prescribed NSAID, to treat OA pain. PENNSAID 2% also includes DMSO, a penetrating agent that helps ensure that diclofenac sodium is absorbed through the skin to the site of inflammation and pain. PENNSAID 2% is the only topical NSAID offered with the convenience of a metered-dose pump, which ensures that the patient would get the correct amount of PENNSAID 2% solution each time. The company has an exclusive supply agreement with Nuvo Research Inc. (Nuvo). Under the supply agreement, Nuvo would manufacture and supply PENNSAID 2% to it. RAYOS/LODOTRA RAYOS, known as LODOTRA outside the United States, is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults particularly wh

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HZNP:US $32.57 USD +0.67

HZNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $83.41 USD +0.24
Pfizer Inc $34.30 USD +0.19
View Industry Companies
 

Industry Analysis

HZNP

Industry Average

Valuation HZNP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.2x
Price/Book 6.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HORIZON PHARMA PLC, please visit www.horizonpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.